Literature DB >> 29466531

Association of Increased Chronicity of Depression With HIV Appointment Attendance, Treatment Failure, and Mortality Among HIV-Infected Adults in the United States.

Brian W Pence1, Jon C Mills1, Angela M Bengtson2, Bradley N Gaynes3, Tiffany L Breger1, Robert L Cook4,5, Richard D Moore6, David J Grelotti7, Conall O'Cleirigh8,9,10, Michael J Mugavero11,12.   

Abstract

Importance: Depression commonly affects adults with HIV and complicates the management of HIV. Depression among individuals with HIV tends to be chronic and cyclical, but the association of this chronicity with HIV outcomes (and the related potential for screening and intervention to shorten depressive episodes) has received little attention. Objective: To examine the association between increased chronicity of depression and multiple HIV care continuum indicators (HIV appointment attendance, treatment failure, and mortality). Design, Setting, and Participants: The study comprised an observational clinical cohort of 5927 patients with 2 or more assessments of depressive severity who were receiving HIV primary care at 6 geographically dispersed US academic medical centers from September 22, 2005, to August 6, 2015. Main Outcomes and Measures: Missing a scheduled HIV primary care visit, detectable HIV RNA viral load (≥75 copies/mL), and all-cause mortality. Consecutive depressive severity measures were converted into a time-updated measure: percentage of days with depression (PDD), following established methods for determining depression-free days.
Results: During 10 767 person-years of follow-up, the 5927 participants (5000 men, 926 women, and 1 intersex individual; median age, 44 years [range, 35-50 years]) had a median PDD of 14% (interquartile range, 0%-48%). During follow-up, 10 361 of 55 040 scheduled visits (18.8%) were missed, 6191 of 28 455 viral loads (21.8%) were detectable, and the mortality rate was 1.5 deaths per 100 person-years. Percentage of days with depression showed a dose-response relationship with each outcome. Each 25% increase in PDD led to an 8% increase in the risk of missing a scheduled appointment (risk ratio, 1.08; 95% CI, 1.05-1.11), a 5% increase in the risk of a detectable viral load (risk ratio, 1.05; 95% CI, 1.01-1.09), and a 19% increase in the mortality hazard (hazard ratio, 1.19; 95% CI, 1.05-1.36). These estimates imply that, compared with patients who spent no follow-up time with depression (PDD, 0%), those who spent the entire follow-up time with depression (PDD, 100%) faced a 37% increased risk of missing appointments (risk ratio, 1.37; 95% CI, 1.22-1.53), a 23% increased risk of a detectable viral load (risk ratio, 1.23; 95% CI, 1.06-1.43), and a doubled mortality rate (hazard ratio, 2.02; 95% CI, 1.20-3.42). Conclusions and Relevance: Greater chronicity of depression increased the likelihood of failure at multiple points along the HIV care continuum. Even modest increases in the proportion of time spent with depression led to clinically meaningful increases in negative outcomes. Clinic-level trials of protocols to promptly identify and appropriately treat depression among adults living with HIV should be conducted to understand the effect of such protocols on shortening the course and preventing the recurrence of depressive illness and improving clinical outcomes.

Entities:  

Mesh:

Year:  2018        PMID: 29466531      PMCID: PMC5875308          DOI: 10.1001/jamapsychiatry.2017.4726

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  55 in total

1.  Psychiatric comorbidity in depressed HIV-infected individuals: common and clinically consequential.

Authors:  Bradley N Gaynes; Julie O'Donnell; Elise Nelson; Amy Heine; Anne Zinski; Malaika Edwards; Teena McGuinness; Modi A Riddhi; Charita Montgomery; Brian W Pence
Journal:  Gen Hosp Psychiatry       Date:  2015-04-07       Impact factor: 3.238

2.  Depression and human immunodeficiency virus infection are risk factors for incident heart failure among veterans: Veterans Aging Cohort Study.

Authors:  Jessica R White; Chung-Chou H Chang; Kaku A So-Armah; Jesse C Stewart; Samir K Gupta; Adeel A Butt; Cynthia L Gibert; David Rimland; Maria C Rodriguez-Barradas; David A Leaf; Roger J Bedimo; John S Gottdiener; Willem J Kop; Stephen S Gottlieb; Matthew J Budoff; Tasneem Khambaty; Hilary A Tindle; Amy C Justice; Matthew S Freiberg
Journal:  Circulation       Date:  2015-09-10       Impact factor: 29.690

3.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

4.  Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.

Authors:  Stephen R Cole; Sonia Napravnik; Michael J Mugavero; Bryan Lau; Joseph J Eron; Michael S Saag
Journal:  Am J Epidemiol       Date:  2009-12-09       Impact factor: 4.897

5.  The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals.

Authors:  Mary K Tegger; Heidi M Crane; Kenneth A Tapia; Karina K Uldall; Sarah E Holte; Mari M Kitahata
Journal:  AIDS Patient Care STDS       Date:  2008-03       Impact factor: 5.078

6.  Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.

Authors:  Nikolas Wada; Lisa P Jacobson; Mardge Cohen; Audrey French; John Phair; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2013-01-03       Impact factor: 4.897

7.  Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women.

Authors:  Judith A Cook; Dennis Grey; Jane Burke; Mardge H Cohen; Alejandra C Gurtman; Jean L Richardson; Tracey E Wilson; Mary A Young; Nancy A Hessol
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

8.  Relation of lifetime trauma and depressive symptoms to mortality in HIV.

Authors:  Jane Leserman; Brian Wells Pence; Kathryn Whetten; Michael J Mugavero; Nathan M Thielman; Marvin S Swartz; Dalene Stangl
Journal:  Am J Psychiatry       Date:  2007-11       Impact factor: 18.112

9.  Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment.

Authors:  Joseph E Schumacher; Cheryl McCullumsmith; Michael J Mugavero; Paige E Ingle-Pang; James L Raper; James H Willig; Zhiying You; D Scott Batey; Heidi Crane; Sarah T Lawrence; Charles Wright; Glenn Treisman; Michael S Saag
Journal:  AIDS Behav       Date:  2013-10

10.  The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART.

Authors:  Viviane D Lima; Josie Geller; David R Bangsberg; Thomas L Patterson; Mark Daniel; Thomas Kerr; Julio S G Montaner; Robert S Hogg
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

View more
  50 in total

1.  Clinical correlates of depression chronicity among people living with HIV: What is the role of suicidal ideation?

Authors:  Griffin A Tyree; Florin Vaida; Sidney Zisook; William C Mathews; David J Grelotti
Journal:  J Affect Disord       Date:  2019-07-30       Impact factor: 4.839

Review 2.  Brain PET Imaging: Value for Understanding the Pathophysiology of HIV-associated Neurocognitive Disorder (HAND).

Authors:  Sanhita Sinharay; Dima A Hammoud
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

3.  Depression and all-cause mortality risk in HIV-infected and HIV-uninfected US veterans: a cohort study.

Authors:  K So-Armah; S K Gupta; S Kundu; J C Stewart; J L Goulet; A A Butt; J J Sico; V C Marconi; S Crystal; M C Rodriguez-Barradas; M Budoff; C L Gibert; C-Ch Chang; R Bedimo; M S Freiberg
Journal:  HIV Med       Date:  2019-03-29       Impact factor: 3.180

Review 4.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

5.  The Current State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging.

Authors:  Stephanie Shiau; Alexis A Bender; Jane A O'Halloran; Erin Sundermann; Juhi Aggarwal; Keri N Althoff; Jason V Baker; Steven Deeks; Linda P Fried; Stephen Karpiak; Maile Y Karris; Thomas D Marcotte; Jean B Nachega; Joseph B Margolick; Kristine M Erlandson; David J Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2020-09-23       Impact factor: 2.205

6.  Pharmacologic Treatment of Psychiatric Disorders and Time With Unsuppressed HIV Viral Load in a Clinical HIV Cohort.

Authors:  Matthew E Levy; Anne K Monroe; Michael A Horberg; Debra A Benator; Sherry Molock; Rupali K Doshi; Lindsey Powers Happ; Amanda D Castel
Journal:  J Acquir Immune Defic Syndr       Date:  2019-11-01       Impact factor: 3.731

Review 7.  Psychosocial risk and management of physical diseases.

Authors:  Neil Schneiderman; Roger C McIntosh; Michael H Antoni
Journal:  J Behav Med       Date:  2019-01-10

8.  Burden of Depression in Outpatient HIV-Infected adults in Sub-Saharan Africa; Systematic Review and Meta-analysis.

Authors:  S M Lofgren; D J Bond; N Nakasujja; D R Boulware
Journal:  AIDS Behav       Date:  2020-06

9.  Depressive Symptom Trajectories Among People Living with HIV in a Collaborative Care Program.

Authors:  Douglas Gunzler; Steven Lewis; Allison Webel; Mallika Lavakumar; Diana Gurley; Katherine Kulp; McKenzie Pile; Victoria El-Hayek; Ann Avery
Journal:  AIDS Behav       Date:  2020-06

10.  Prevalence of HIV Viral Load Suppression Among Psychiatric Inpatients with Comorbid Substance Use Disorders.

Authors:  D M Coviello; R Lovato; K Apostol; M M Eisenberg; D S Metzger; R Szucs-Reed; N Kiryankova-Dalseth; D Kelly; A Jackson; M Plano; M B Blank
Journal:  Community Ment Health J       Date:  2018-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.